2291 (2291) Fair Value & Analysis

Healthcare · Market cap HK$3.7B

2 2291 2291 · HK

PriceHK$10.65

Fair ValueHK$17.57

Upside+65.0%

Quality52/100

Watch 2291 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$13.17 – HK$21.14

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +9.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$8.67 – HK$26.07 · fair‑value band HK$13.17 – HK$21.14 · the HK$10.65 price screens below the HK$17.57 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2291 (2291) currently trades at HK$10.65, while our model-based Fair Value estimate is HK$17.57 — implying the stock looks roughly 65.0% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

Over the trailing twelve months, 2291 generated revenue of HK$528M at a net margin of 45.4%. Revenue declined 10.9% year over year. It earns a return on equity of 11.9%. The balance sheet holds a net cash position of HK$1.2B. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$528M

Revenue growth (YoY) -10.9%

Net margin 45.4%

Return on equity 11.9%

Free cash flow HK$145M FY2025

P/E ratio 13.3

More key figures

Operating margin 29.5%

EPS (TTM) HK$0.0200

Dividend yield 4.9%

EPS growth (YoY) -45.6%

Net cash HK$1.2B FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

2291 reported revenue of HK$528M in FY2025 versus HK$223M in FY2021, a compound +24.1%/yr. Reported net income was HK$240M in FY2025, compounding +42.2%/yr from FY2021.

Revenue +24.1%/yr

FY21 HK$223M

FY22 HK$248M

FY23 HK$326M

FY24 HK$472M

FY25 HK$528M

Net income +42.2%/yr

FY21 HK$58.7M

FY22 −HK$19.8M

FY23 HK$152M

FY24 HK$246M

FY25 HK$240M

Is 2291 fairly valued? → Check now

Similar stocks

6 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
ABT ABT	1,600 MXN	1,231 MXN	-23%
Abbott Laboratories, ABTT34	R$38.22	R$30.39	-20%
Stryker Corporation S1YK34	R$79.21	R$43.74	-45%
Medtronic plc MDT	$81.67	$60.02	-27%
Boston Scientific Corporation B1SX34	R$229.30	R$43.33	-81%
Edwards Lifesciences Corporation EW	$85.98	$41.02	-52%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2291 (2291) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$17.57 versus a price of HK$10.65 — about +65% (undervalued). Model-based estimate, not financial advice.

What is the fair value of 2291?

Our model-based fair value for 2291 is HK$17.57 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$10.65.

What is the quality score of 2291?

2291 has a Quality Score of 52/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 2291 (2291)?

2291 reported trailing-twelve-month revenue of about HK$528M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 2291?

The net profit margin of 2291 is about 45.4%, meaning it keeps roughly 45.4% of revenue as net income. Based on the latest reported figures.

Does 2291 pay a dividend?

2291 currently shows a dividend yield of about 4.90% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.